CA2901436A1 - Ligands de liaison allosteriques de la proproteine convertase subtilisine/kexine de type 9 (pcsk9) utilisables en vue de la modulation des niveaux seriques de lipoproteines de basse densite (ldl) - Google Patents
Ligands de liaison allosteriques de la proproteine convertase subtilisine/kexine de type 9 (pcsk9) utilisables en vue de la modulation des niveaux seriques de lipoproteines de basse densite (ldl) Download PDFInfo
- Publication number
- CA2901436A1 CA2901436A1 CA2901436A CA2901436A CA2901436A1 CA 2901436 A1 CA2901436 A1 CA 2901436A1 CA 2901436 A CA2901436 A CA 2901436A CA 2901436 A CA2901436 A CA 2901436A CA 2901436 A1 CA2901436 A1 CA 2901436A1
- Authority
- CA
- Canada
- Prior art keywords
- ser
- thr
- trp
- compound
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361765423P | 2013-02-15 | 2013-02-15 | |
US61/765,423 | 2013-02-15 | ||
US201361836381P | 2013-06-18 | 2013-06-18 | |
US61/836,381 | 2013-06-18 | ||
PCT/US2014/016640 WO2014127316A2 (fr) | 2013-02-15 | 2014-02-15 | Ligands de liaison allostériques de la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) utilisables en vue de la modulation des niveaux sériques de lipoprotéines de basse densité (ldl) |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2901436A1 true CA2901436A1 (fr) | 2014-08-21 |
Family
ID=51354696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2901436A Abandoned CA2901436A1 (fr) | 2013-02-15 | 2014-02-15 | Ligands de liaison allosteriques de la proproteine convertase subtilisine/kexine de type 9 (pcsk9) utilisables en vue de la modulation des niveaux seriques de lipoproteines de basse densite (ldl) |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2956154A4 (fr) |
JP (1) | JP2016508722A (fr) |
KR (1) | KR20150127622A (fr) |
CN (1) | CN105378159A (fr) |
AU (1) | AU2014216091A1 (fr) |
CA (1) | CA2901436A1 (fr) |
HK (1) | HK1219048A1 (fr) |
IL (1) | IL240583A0 (fr) |
SG (1) | SG11201506336XA (fr) |
WO (1) | WO2014127316A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
EP2968443B1 (fr) | 2013-03-15 | 2021-09-29 | Protagonist Therapeutics, Inc. | Analogues d'hepcidine et leurs utilisations |
NZ726337A (en) | 2014-05-16 | 2023-10-27 | Protagonist Therapeutics Inc | Α4β7 integrin thioether peptide antagonists |
CA2955460A1 (fr) | 2014-07-17 | 2016-01-21 | Protagonist Therapeutics, Inc. | Peptides inhibiteurs par voie orale du recepteur de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires de l'intestin |
EP3182971A4 (fr) | 2014-08-21 | 2018-04-25 | SRX Cardio, LLC | Composition et procédés d'utilisation de petites molécules en tant que ligands de liaison pour la modulation de l'activité proprotéine convertase subtilisine/protéine kexine de type 9 (pcsk9) |
EP3201217A4 (fr) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Nouveaux peptides monomères et dimères cycliques possédant une activité antagoniste de l'intégrine |
JP2017535527A (ja) | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス, インコーポレイテッド | 新規のα4β7ペプチド単量体及び二量体拮抗薬 |
MA41022A (fr) * | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
EP3337497B1 (fr) | 2015-08-21 | 2023-07-12 | SRX Cardio, LLC | Composition et procédés d'utilisation de nouveaux petits composés organiques de phénylalanine pour moduler directement l'activité de la protéine pcsk9 |
WO2017034990A1 (fr) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition et procédés d'utilisation de petites molécules de type tétrahydroisoquinoline pour se lier à pcsk9 et moduler l'activité protéique de pcsk9 |
WO2017034997A1 (fr) * | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Modulateurs phénylpipérazine proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et leur utilisation |
US20180289843A1 (en) * | 2015-09-28 | 2018-10-11 | Agency For Science, Technology And Research | Coating for metal nanoparticles |
US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
WO2017147328A1 (fr) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Composés se liant à la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) |
CA3017926C (fr) | 2016-03-23 | 2023-10-10 | Protagonist Therapeutics, Inc. | Procedes de synthese d'antagonistes de peptide .alpha.4.beta.7 |
BR112018076242A2 (pt) | 2016-06-24 | 2019-03-26 | Hoffmann La Roche | inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1 |
TW201823222A (zh) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | 化合物、醫藥組成物及其用途 |
TW201920234A (zh) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | 類鴉片促效劑肽及其用途 |
CA3089868A1 (fr) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Mimetiques d'hepcidine conjugues |
MX2021008533A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
EP3997105A4 (fr) | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires |
CA3167751A1 (fr) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Inhibiteurs peptidiques du recepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires |
PE20240631A1 (es) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7928189B2 (en) * | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
BR112012007241A2 (pt) * | 2009-10-01 | 2019-09-24 | Cadila Healthcare Ltd Soc Indiana | compostos , composição farmacêutica, método para tratar desordens, uso dos compostos, medicamento, método para selecionar inibidores com pequenas moléculas de pcsk9 e pequenas moléculas |
CN102206249B (zh) * | 2011-04-26 | 2013-07-03 | 中国农业科学院哈尔滨兽医研究所 | 乙型脑炎病毒ns1蛋白特异性b细胞抗原表位多肽及其应用 |
-
2014
- 2014-02-15 KR KR1020157025152A patent/KR20150127622A/ko not_active Application Discontinuation
- 2014-02-15 AU AU2014216091A patent/AU2014216091A1/en not_active Abandoned
- 2014-02-15 CA CA2901436A patent/CA2901436A1/fr not_active Abandoned
- 2014-02-15 CN CN201480017801.7A patent/CN105378159A/zh active Pending
- 2014-02-15 SG SG11201506336XA patent/SG11201506336XA/en unknown
- 2014-02-15 JP JP2015558178A patent/JP2016508722A/ja active Pending
- 2014-02-15 EP EP14751148.9A patent/EP2956154A4/fr not_active Withdrawn
- 2014-02-15 WO PCT/US2014/016640 patent/WO2014127316A2/fr active Application Filing
-
2015
- 2015-08-13 IL IL240583A patent/IL240583A0/en unknown
-
2016
- 2016-06-20 HK HK16107087.1A patent/HK1219048A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2956154A4 (fr) | 2016-07-27 |
SG11201506336XA (en) | 2015-09-29 |
IL240583A0 (en) | 2015-09-24 |
WO2014127316A2 (fr) | 2014-08-21 |
EP2956154A2 (fr) | 2015-12-23 |
JP2016508722A (ja) | 2016-03-24 |
WO2014127316A4 (fr) | 2014-12-04 |
KR20150127622A (ko) | 2015-11-17 |
WO2014127316A3 (fr) | 2014-10-09 |
CN105378159A (zh) | 2016-03-02 |
AU2014216091A1 (en) | 2015-09-03 |
HK1219048A1 (zh) | 2017-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2901436A1 (fr) | Ligands de liaison allosteriques de la proproteine convertase subtilisine/kexine de type 9 (pcsk9) utilisables en vue de la modulation des niveaux seriques de lipoproteines de basse densite (ldl) | |
US11771710B2 (en) | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | |
US10287317B2 (en) | Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels | |
JP2019108389A (ja) | アテローム性硬化症の処置方法 | |
US11944619B2 (en) | Phenylalanine small organic compounds to directly modulate PCSK9 protein activity | |
US10980801B2 (en) | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | |
JP6641356B2 (ja) | 疾患の予防及び治療のための方法及び組成物 | |
US20210309613A1 (en) | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity | |
JP2019104744A (ja) | コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20200217 |